Additional cases of Crimean-Congo haemorrhagic fever (CCHF), a potentially life threatening tick-borne viral disease, have been reported in the EU/EEA, according to new data published by ECDC. Experts have warned of an increased risk of transmission on the continent.
On 11 January 2023, Uganda declared that the Ebola disease outbreak caused by the Sudan ebolavirus was over. The declaration was made after 42 days passed without any case reported, since the last case was released from care.
ECDC is actively monitoring the Ebola outbreak in Uganda through its epidemic intelligence activities and regular communication with Africa CDC, WHO (Ebola Disease caused by Sudan virus – Uganda) and GOARN partners.
In August 2020, Global Outbreak and Alert and Response Network (GOARN) sent a request for assistance for epidemiologists to be deployed to the Democratic Republic of the Congo (DRC) to support the Ebola virus disease (EVD) outbreak response in the Equateur Province.
As of 14 February 2021, seven cases of Ebola virus disease (EVD) have been reported in Guinea, including three deaths. Among these cases, three have been laboratory-confirmed at the national reference laboratory. Four cases remain in isolation at healthcare facilities.
As of 14 February 2021, four cases of Ebola virus disease (EVD), including two deaths, have been reported in the North Kivu province in the eastern part of the Democratic Republic of the Congo (DRC), where a large outbreak was declared over in June 2020. Two health zones are currently affected: Biena and Katwa.
On 18 November 2020, the 11th outbreak of Ebola virus disease in the Democratic Republic of the Congo (DRC) was declared over. There have been 130 cases, including 55 deaths reported from 13 health zones in the Equateur Province since the beginning of the outbreak almost six months ago.
On 1 June 2020, a new outbreak of Ebola virus disease was declared in Wangata Health Zone, near Mbandaka, the regional capital of Equateur Province in the western region of DRC.
Two out of the four drugs tested in a multi-drug randomised control trial have been found more effective in treating Ebola, the World Health Organization announced on Monday. The Data and Safety Monitoring Board, an independent body that has been reviewing interim safety and efficacy data, has therefore recommended that the study be stopped and that all future patients be randomized to receive either REGN-EB3 or mAb114, in what is being considered an extension phase of the study.